1. Ahn YM, Kim K, Kim YS. Three cases of reversible agra nulocytosis after treatment with lamotrigine. Psychiatry Investig. 2008; 5: 121–123.
2.
Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27(3): 173–184.
3.
Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397–1400.
4.
de Camargo OA, Bode H. Agranulocytosis associated with lamotrigine. BMJ 1999; 318: 1179.
5.
Ceylan M, Ceylan O. Rare combination of adverse effects associated with lamotrigine treatment. J Neurol Res. 2018; 8(1–2): 10–12.
6.
Damiani JT, Christensen RC. Lamotrigine-associated neu tropenia in a geriatric patient. Am J Geriatr Psychiatry 2000; 8: 346.
7.
Das P, Ramaswamy S, Arora M, Samuels I, Gabel TL. Lamotri gine-induced neutropenia in a woman with schizoaffective disorder. J Clin Psychiatry. 2007; 9: 471–472.
8.
Fadul CE, Meyer LP, Jobst BC, Cornell CJ, Lewis LD. Agra nulocytosis associated with lamotrigine in a patient with low-grade glioma. Epilepsia 2002; 43: 199–200.
9.
Fernández-Galán A, Martín-Núñez G, Castellanos F, López--López M. Agranulocitosis asociada a tratamiento con la motrigine. Med Clin Barc 2000; 115; 759.
10.
Flanagan R.J., Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol 2008; 23 (supl. 1): 27–41.
11.
Jarema M. Psychiatria. Podręcznik dla studentów medycyny. Wydawnictwo Lekarskie PZWL, wyd. II, 2016: 187.
12.
Kilbas S. Lamotrigine-induced leucopenia. Epileptic Disord. 2006; 8: 317.
13.
Lambert O, Veyrac G, Armand C, Bourlon S, Bourin M, Jolliet P. Lamotrigine-induced neutropenia following two attempts to increase dosage above 50mg/day with recovery between epi sodes. Adverse Drug Reacti Toxicol Rev 2002; 21 (3):157–159.
14.
Lamilept. Charakterystyka Produktu Leczniczego. Data za twierdzenia: 18.04.2012.
15.
LeDrew K, Phillips L, Hogan M, MacCallum A. Lamotrigine induced neutropenia. Can J Psychiatry 2005; 50: 242.
16.
Lithium Carbonicum GSK. Charakterystyka Produktu Lecz niczego. Data zatwierdzenia: 17.12.2019 r.
17.
Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of longterm lamotrigine in epilepsy. Epilepsia 1997; 38: 881–886.
18.
Nazer LH, Shankar G, Al-Haj Ali B, Al-Najjar T. Fatal agra nulocytosis associated with psychotropic medication use. Am J Health-Syst Pharm. 2012; 69, 863–867.
19.
Nicholson RJ, Kelly KP, Grant IS. Leucopenia associated with lamotrigine. BMJ 1995; 310: 504.
20.
Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as an adjunct to paroxetine in acute depression. J Clin Psychiatry 2002; 63(4): 337–344.
21.
Oyesanmi O., Kunkel E.J., Monti D.A., Field H.L. Hematologic side effects of psychotropics. Psychosomatics 1999; 40 (5): 414–421.
22.
Pawełczyk T, Pawełczyk A, Rabe-Jabłońska J. Hematologiczne działania niepożądane leków psychotropowych – wskazówki dla lekarza praktyka. Psychiatria 2011, 8, nr, 97–109.
23.
Seo HJ, Chiesa A, Lee SJ, Patkar A, Han Ch, Masand PS, et al. Safety and Tolerability of Lamotrigine: Results From 12 Placebo-Controlled Clinical Trials and Clinical Implications. Clin Neuropharmacol. 2011; 34(1): 39–47.
24.
Solvason HB. Agranulocytosis associated with lamotrigine. Am J Psychiatry 2000; 157: 1704.
25.
Tourian L, Margolese HC. Late-onset agranulocytosis in a pa tient treated with clozapine and lamotrigine. J Clin Psycho pharmacol. 2011; 31(5): 665–667.
26.
Tuszewska M, Rybakowski J. Normotymiczne działanie la motryginy. Farmakoterapia w Psychiatrii i Neurologii, 2004, 3, 325–334.
27.
Ural AU, Avcu F, Gökçil Z, Nevruz O, Cetin T. Leukopenia and thromcytopenia possibly associated with lamotrigine use in a patient. Epileptic Disord 2005; 7: 33–35.
28.
Urban AE, Wiglusz MS, Cubała WJ, Landowski J, Krysta K. Rapid-onset agranulocytosis in a patient treated with clo zapine and lamotrigine. Psychiatria Danubina, 2015; 27(1): 459–461.
29.
Venlectine. Charakterystyka Produktu Leczniczego. Data zatwierdzenia: 22.03.2013.
